Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Motohiko Maruno

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 14, 2006
[Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study]Ryo Nishikawa, Soichiro Shibui, Motohiko Maruno, et al.
Cancer Immunology, Immunotherapy : CII|November 7, 2024
Spontaneous high clonal expansion of Wilms' tumor gene 1-specific cytotoxic T-lymphocytes in patients with Wilms' tumor gene 1-expressing solid tumorSoyoko Morimoto, Yukie Tanaka, Jun Nakata, et al.
Cancer Science|December 1, 2011
Biased usage of T cell receptor β-chain variable region genes of Wilms' tumor gene (WT1)-specific CD8+ T cells in patients with solid tumors and healthy donorsSoyoko Morimoto, Yoshihiro Oka, Akihiro Tsuboi, et al.
Cancer Science|October 27, 2004
Overexpression of the Wilms' tumor gene W T1 in primary astrocytic tumorsYusuke Oji, Tsuyoshi Suzuki, Yoko Nakano, et al.
Journal of Neurosurgery|May 2, 2008
Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiformeShuichi Izumoto, Akihiro Tsuboi, Yoshihiro Oka, et al.
Japanese Journal of Clinical Oncology|April 14, 2006
A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I dataSatoshi Morita, Yoshihiro Oka, Akihiro Tsuboi, et al.
Anticancer Research|July 24, 2010
A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccinationFumihiro Fujiki, Yoshihiro Oka, Mai Kawakatsu, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 14, 2006
[Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study]Ryo Nishikawa, Soichiro Shibui, Motohiko Maruno, et al.
Cancer Immunology, Immunotherapy : CII|November 7, 2024
Spontaneous high clonal expansion of Wilms' tumor gene 1-specific cytotoxic T-lymphocytes in patients with Wilms' tumor gene 1-expressing solid tumorSoyoko Morimoto, Yukie Tanaka, Jun Nakata, et al.
Cancer Science|December 1, 2011
Biased usage of T cell receptor β-chain variable region genes of Wilms' tumor gene (WT1)-specific CD8+ T cells in patients with solid tumors and healthy donorsSoyoko Morimoto, Yoshihiro Oka, Akihiro Tsuboi, et al.
Cancer Science|October 27, 2004
Overexpression of the Wilms' tumor gene W T1 in primary astrocytic tumorsYusuke Oji, Tsuyoshi Suzuki, Yoko Nakano, et al.
Journal of Neurosurgery|May 2, 2008
Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiformeShuichi Izumoto, Akihiro Tsuboi, Yoshihiro Oka, et al.
Japanese Journal of Clinical Oncology|April 14, 2006
A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I dataSatoshi Morita, Yoshihiro Oka, Akihiro Tsuboi, et al.
Anticancer Research|July 24, 2010
A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccinationFumihiro Fujiki, Yoshihiro Oka, Mai Kawakatsu, et al.
Pageof 4